David B. Weiner - 13 May 2022 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role
Director
Signature
/s/ David B. Weiner
Issuer symbol
INO
Transactions as of
13 May 2022
Transactions value $
-$17,550
Form type
4
Filing time
17 May 2022, 16:32:21 UTC
Previous filing
14 Mar 2022
Next filing
11 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INO Common Stock Options Exercise +18K +2.04% 902K 13 May 2022 Direct F1
transaction INO Common Stock Sale -$17.6K -9K -1% $1.95 893K 16 May 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Restricted Stock Unit Options Exercise $0 -18K -100% $0.00* 0 13 May 2022 Common Stock 18K Direct F1
transaction INO Restricted Stock Unit Award $0 +19K $0.00 19K 16 May 2022 Common Stock 19K Direct F3, F4
transaction INO Common Stock Options Award $0 +28K $0.00 28K 16 May 2022 Common Stock 28K $1.89 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer.
F3 Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023.
F4 This grant was made pursuant to the issuer's non-employee director compensation policy.
F5 Options to vest 100% on May 16, 2023.